Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech Backers Are Learning to Live with Exit-by-Earn-out

This article was originally published in Start Up

Executive Summary

Despite a few bright spots, the fundraising environment remains difficult for many venture investors. Biotechs that went public during the 2005-2007 window have largely underperformed, despite hitting the stock exchanges with what plenty of CEOs and VCs felt were artificially low prices negotiated by an oligarchy of biotech IPO buyers. Moreover, pharmaceutical companies have been buying fewer, not more, biotechs - even as more companies are seemingly created with acquisition, not IPO, in mind. Meanwhile, the M&A deals that do occur are increasingly risk-sharing affairs that resemble alliances, replete with earn-out payments triggered by development, regulatory, or commercial milestones. In short: good venture exits have been extremely hard to come by. And data from Elsevier's Strategic Transactions analyzed by START-UP suggest that although these risk-sharing deal structures may be a by-product of a miserable economy, they are likely to stick around regardless of any economic turnaround.
Advertisement

Related Content

Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Daiichi's Handsome Buyout Price Validates Plexxikon's Business Model
In the Midst Of A Shakeout, Biotech VCs Must Embrace New Partners, New Math
Trophos Blueprints Path To Exit With Actelion Option Deal
As Some VCs Run On Empty, Others Are Topping Off The Tank
Ex-Congressman Gephardt Lobbies for Medical Innovation Czar, Federal Help for VCs
Valuation Watch: As Biopharma IPOs Return, Does Value?
Anthera Takes A "Haircut" And Delays Its Planned Initial Stock Offering
Ironwood IPO Raises Plenty Of Cash And Plenty Of Questions For Biotech Investors
Private Biotech M&A Review: Has the Market Lost Steam?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC091935

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel